Linaprazan

In the global diagnosis and treatment system for urinary system diseases, highly selective M3 receptor antagonists are a core drug category for improving the clinical prognosis of overactive bladder (OAB). As a differentiated product in this field, linadadine can highly specifically block M3 cholinergic receptors on bladder smooth muscle and inhibit involuntary detrusor contraction, while greatly reducing the binding probability with M receptors in salivary glands, cardiovascular system and other parts. Thus, while relieving symptoms of frequent urination, urgent urination and urge urinary incontinence in OAB patients, it can significantly reduce common adverse reactions such as dry mouth and constipation, and is especially suitable for long-term use in elderly OAB patients with underlying diseases.

At present, the overall global prevalence of overactive bladder exceeds 10%, among which the prevalence among people over 40 years old rises to 17%, driving the continuous expansion of the highly selective anticholinergic API market. As a representative product of the third-generation M3 receptor antagonists, linadadine's global market size has exceeded USD 320 million in 2023, with a compound annual growth rate remaining above 12%. At present, 3 generic drug manufacturers have obtained marketing approval in the European and American markets, and domestic generic drug R&D is in the declaration stage. With the improvement of clinical awareness and the expansion of medical insurance coverage, the domestic market demand for linadadine is expected to maintain a growth rate of more than 20% in the next three years.

The original developer of linadadine is Astellas Pharma Japan, with the original brand name Staybla. The core compound patents expire in 2026, 2027 and 2028 in Japan, the United States and Europe respectively. The mainstream dosage form of the original product is oral tablet, with two specifications of 2.5mg and 5mg. It has been included in the Japanese Pharmacopoeia Reference Preparation Catalog and also收录 in the FDA Orange Book. Up to now, no domestic enterprise has obtained the API Master File (DMF) approval for this variety, and no corresponding preparation product has been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for linadadine, with most products in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the reference standard supply needs of pharmaceutical enterprises in the whole process of R&D, quality research and declaration.